Kindeva joins forces with Rocket Science Health to pioneer new Intranasal Delivery Platform

Kindeva, a global CDMO and drug delivery expert, and Rocket Science Health (RSH), a Canadian technology healthcare company, have joined forces to find partners to develop a new intranasal delivery platform. RSH’s cutting-edge technology, combined with Kindeva’s CDMO capabilities, will supercharge the product journey as RSH prepares for commercial readiness.

The non-exclusive agreement will see Kindeva and RSH identify partners for the development of the ‘RSH Olfactory Delivery Device,’ a dual nostril intranasal platform used for precisely targeting specific regions of the nasal cavity.

The device has the ability to deposit the majority of a drug dose into the Olfactory Clefts. The Olfactory Clefts are both a desirable target for drug deposition, and yet, historically a difficult location to reach due to the complex human nasal anatomy.

Early research* suggest the device has the potential to achieve high deposition by ejecting a laminar stream, as compared to conventional intranasal treatments which eject a plume spray or mist. Further, the RSH technology overcomes complex nasal anatomy through the device’s proprietary dispensing tips that extend past the nasal valve to an optimal vantage point.

Another feature of the RSH technology that sets it apart is attention to human factors to ensure the device is accessible, comfortable, and easy to use correctly for accurate dosing, especially among cognitively and or physically impaired patients, and for self-administration. Kenneth Irving, Rocket Science Health’s Founder and CEO said of the news,

“A personal experience with an unreliable delivery method opened my eyes to the influence of drug devices on health outcomes. That realization led to the founding of Rocket Science Health and nearly a decade of rethinking intranasal delivery. Knowing subregions of the nasal cavity provide access to different organ systems, most notably the CNS via the Olfactory Clefts, we redesigned the fluidics and user experience to enable precise, targeted delivery.

Now, we are ready to bring this technology into clinical trials for advancing dose dependent medicine. Kindeva stood out not only for their track record of supporting drug developers through the trial process, but for their history and shared commitment to making meaningful innovations widely accessible.”

Kindeva is committed to being a leader in the growing intranasal drug delivery space and sees RSH’s technology as a breakthrough innovation.  Kindeva’s expertise in manufacturing and regulatory pathways will be crucial in RSH’s journey to receiving FDA approval, and its collaboration will extend the technology’s global reach when it is eventually ready for commercial distribution.

Commenting on the partnership, David Stevens, Chief Commercial and Operating Officer at Kindeva, said: “Kindeva’s proven expertise and track record of developing and commercializing novel drug delivery devices makes us the ideal partner to support Rocket Science Health’s new Olfactory device. I am incredibly excited to collaborate with the fantastic Rocket team as they look to realize their ambition to create a step change improvement in nasal drug delivery.”

About Kindeva: 

At Kindeva, we manufacture more tomorrows for patients worldwide. With best-in-class facilities and comprehensive CDMO services, we offer more than manufacturing.

Our global network of 10 manufacturing and R&D sites offer exceptional integrated knowledge and capabilities, including Annex 1-compliant state-of-the-art aseptic fill finish capacity and next-generation sustainable inhalation propellant technology.

By combining expertise in injectable, pulmonary, nasal, and dermal drug delivery, we help meet the demands of today and deliver the possibilities of tomorrow.

About Rocket Science: 

Rocket Science Health is a Canadian healthcare technology company pioneering intranasal drug delivery solutions to address brain health and central nervous system (CNS) disorders. Founded in 2019 and headquartered in Victoria, British Columbia, the company focuses on developing human-centric medical devices that enable targeted delivery of therapeutics directly to the brain via the olfactory region.